logo-loader
viewNemaura Medical Inc

Full interview: Nemaura Medical reveals details of upcoming European launch and recent patient feedback

Nemaura Medical Inc (NASDAQ:NMRD) Vice President of Strategy & Strategic Alliances Dr Fred Schaebsdau tells Proactive the medical technology company is targeting a commercial launch for its flagship SugarBEAT continuous glucose monitor in the UK and in Ireland in January 2020.

Dr Schaebsdau adds that recently, the Nemaura team presented positive feedback from its first patient-user experiences at the 55th Annual Meeting of the European Association for the Study of Diabetes.

Quick facts: Nemaura Medical Inc

Price: 4.99 USD

NASDAQ:NMRD
Market: NASDAQ
Market Cap: $103.83 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Nemaura Medical Inc named herein, including the promotion by the Company of Nemaura Medical Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Fidelity Minerals sees exciting road ahead for company with...

Fidelity Minerals (CVE: FMN) CEO Ian Graham joined Steve Darling from Proactive Vancouver on Skype to provide a corporate update. Graham discussed the latest on the recent sale of their Cerro Dorado asset and why they decided to do a share consolidation. Graham also discusses the shift in...

9 hours, 31 minutes ago

2 min read